Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Top Cited Papers
Open Access
- 29 February 2020
- journal article
- research article
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in BioScience Trends
- Vol. 14 (1) , 69-71
- https://doi.org/10.5582/bst.2020.01020
Abstract
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societiesKeywords
This publication has 16 references indexed in Scilit:
- A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spikeScience Advances, 2019
- Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016BMC Infectious Diseases, 2018
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading ExoribonucleasemBio, 2018
- Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trialTrials, 2018
- Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus InfectionThe Journal of Immunology, 2017
- The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune functionBMC Complementary and Alternative Medicine, 2017
- Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus FusionJournal of Virology, 2016
- Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease InhibitorPLoS Pathogens, 2016
- Published by Springer Nature ,2016
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004